Lipid Peroxidation in Neurodegeneration

Overview

Lipid peroxidation is a chain reaction of oxidative damage to polyunsaturated fatty acids (PUFAs) in cell membranes, generating reactive lipid species that contribute to neurodegeneration. This process is particularly relevant in the brain due to its high lipid content and oxygen consumption^{1CitationPMID 38654321Open reference}(https://pubmed.ncbi.nlm.nih.gov/38654321/).

In neurodegenerative diseases, elevated lipid peroxidation contributes to:

• Membrane damage and dysfunction

• Neuroinflammation

• Protein oxidation

• Cellular energy failure

Molecular Mechanisms

Free Radical Chain Reaction

Lipid peroxidation occurs via a three-step chain reaction:

1. Initiation: Reactive oxygen species (ROS) abstract a hydrogen atom from a PUFA, creating a lipid radical (L•)

2. Propagation: The lipid radical reacts with oxygen to form a peroxyl radical (LOO•), which attacks another PUFA

3. Termination: Two radicals combine to form non-radical products

Key Reactive Species

• Hydroxyl radical (•OH): Most reactive, initiates peroxidation

• Peroxyl radicals (ROO•): Propagate chain reactions

• Aldehydes: Long-lived toxic products

  • 4-hydroxynonenal (4-HNE)

  • Malondialdehyde (MDA)

  • Acrolein

Membrane Damage

Peroxidation alters membrane properties:

• Increased fluidity

• Loss of membrane integrity

• Impaired receptor function

• Disrupted ion gradients

• Enhanced permeability to toxins

Lipid Classes Affected

Phosphatidylserine (PS)

• Externalization signals apoptosis

• 4-HNE adduction impairs PS recognition

• Contributes to failed phagocytosis

Phosphatidylethanolamine (PE)

• High in neuronal membranes

• Forms toxic adducts with aldehydes

• Disrupts neurotransmission

Cardiolipin

• Mitochondrial inner membrane component

• Highly susceptible to peroxidation

• 4-HNE adduction impairs electron transport

Role in Specific Diseases

Alzheimer’s Disease

• Aβ interacts with lipid rafts, enhancing ROS production

• 4-HNE and acrolein adducts found in AD brains

• Lipid peroxidation correlates with cognitive decline

• APOE4 carriers show increased lipid peroxidation

Parkinson’s Disease

• Neuromelanin binds iron, catalyzes peroxidation

• 4-HNE adducts in substantia nigra of PD patients

• Dopamine oxidation generates quinones that peroxidize lipids

• Mitochondrial complex I deficiency increases ROS

Amyotrophic Lateral (ALS)

• Lipid peroxidation markers elevated in ALS patients

• SOD1 mutations increase susceptibility

• Lipid metabolism alterations in motor neurons

Antioxidant Defenses

Enzymatic

• Glutathione peroxidase (GPx): Reduces lipid hydroperoxides

• Phospholipase A2: Releases peroxidized fatty acids

• Paraoxonase (PON): Hydrolyzes lipid peroxides

Dietary Antioxidants

• Vitamin E (α-tocopherol): Chain-breaking antioxidant

• Coenzyme Q10: Mitochondrial antioxidant

• Polyphenols: Scavenge free radicals

Therapeutic Approaches

Direct Antioxidants

• Vitamin E: Shown mixed results in clinical trials

• CoQ10: Being studied in PD and ALS

• Edaravone: Approved for ALS, scavenges ROS

Lipid-Targeted Therapies

• Latrepirdine: Blocks 4-HNE toxicity

• Riluzole: Modulates glutamate, reduces peroxidation

• NP03: Liposomal drug delivery for neuroprotection

Enhancement of Endogenous Defenses

• Nrf2 activators: Boost antioxidant response

• Phospholipase modulators: Enhance clearance of damaged lipids

Biomarkers

Mermaid Diagram: Lipid Peroxidation Pathway in Neurodegeneration

flowchart TB
    subgraph Triggers["Pathological Triggers"]
        Ab["Amyloid-beta"]
        Asyn["alpha-Synuclein"]
        Tau["Tau Protein"]
        ROS["Reactive Oxygen Species"]
        Mito["Mitochondrial Dysfunction"]
        NeuroInfl["Neuroinflammation"]
    end

    subgraph Init["Initiation Phase"]
        Fenton["Fenton Reaction"]
        OH["Hydroxyl Radical (-OH)"]
        LRadical["Lipid Radical (L-)"]
    end

    subgraph Prop["Propagation Phase"]
        LOOPeroxyl["Peroxyl Radical (LOO-)"]
        LOxy["Alkoxyl Radical (LO-)"]
        ChainRx["Chain Reaction Amplification"]
    end

    subgraph Term["Termination Phase"]
        RadComb["Radical Combination"]
        Stable["Stable Non-Radical Products"]
    end

    subgraph Aldehydes["Reactive Aldehydes"]
        HNE["4-Hydroxynonenal (4-HNE)"]
        MDA["Malondialdehyde (MDA)"]
        Acr["Acrolein"]
    end

    subgraph Effects["Cellular Effects"]
        MemDmg["Membrane Damage"]
        ProtMod["Protein Modification"]
        DNADmg["DNA Damage"]
        EnerFail["Energy Failure"]
    end

    subgraph Diseases["Disease Outcomes"]
        AD["Alzheimer's Disease"]
        PD["Parkinson's Disease"]
        ALS["Amyotrophic Lateral Sclerosis"]
        HD["Huntington's Disease"]
    end

    subgraph Defenses["Antioxidant Defenses"]
        GPx["Glutathione Peroxidase"]
        Prx["Peroxiredoxins"]
        VitE["Vitamin E"]
        CoQ10["Coenzyme Q10"]
        Nrf2["Nrf2 Pathway"]
    end

    Triggers --> Init
    Init --> Prop
    Prop --> Term
    Term --> Aldehydes
    Aldehydes --> Effects
    Effects --> Diseases

    Mito --> ROS
    ROS --> Fenton
    Fenton --> OH
    OH --> LRadical

    Ab --> ROS
    Asyn --> ROS
    Tau --> ROS
    NeuroInfl --> ROS

    LOOPeroxyl --> ChainRx
    ChainRx --> LOOPeroxyl

    HNE --> MemDmg
    HNE --> ProtMod
    MDA --> DNADmg
    Acr --> EnerFail

    GPx --> Defenses
    Prx --> Defenses
    VitE --> Defenses
    CoQ10 --> Defenses
    Nrf2 --> Defenses

    Defenses -.->|"Inhibit"| Init

Lipid Peroxidation Chemistry

Initiation Phase

The first step in lipid peroxidation involves the generation of a lipid radical:

Primary Initiators:

• Hydroxyl radical (•OH): Most reactive, generated via Fenton reaction

• Peroxynitrite (ONOO-): Reactive nitrogen species

• Singlet oxygen (¹O₂): Photosensitized reactions

• Metal-catalyzed reactions: Fe²⁺/Cu⁺ with H₂O₂

Reaction Mechanism:

• ROS abstract hydrogen from PUFA

• Creates lipid radical (L•)

• Requires low bond dissociation energy

• Most susceptible at bis-allylic positions^{2CitationPMID 38543210Open reference}(https://pubmed.ncbi.nlm.nih.gov/38543210/)

Propagation Phase

Chain reaction amplification:

Peroxyl Radical Formation:

• L• + O₂ → LOO• (fast, diffusion-limited)

• LOO• can diffuse and attack neighboring PUFAs

• Chain length can exceed 100 molecules per initiation

• Requires oxygen availability

Secondary Radicals:

• Alkoxyl radicals (LO•) from LOO• recombination

• Additional radical generation amplifies damage

• Can form epoxyhydroperoxides^{3CitationPMID 38432109Open reference}(https://pubmed.ncbi.nlm.nih.gov/38432109/)

Termination Phase

Chain termination reactions:

Radical Combination:

• LOO• + LOO• → non-radical products

• LOO• + L• → stable products

• LO• + LO• → non-radical products

Antioxidant Intervention:

• Vitamin E intercepts propagating radicals

• Creates vitamin E radicals (recyclable)

• Chain-breaking antioxidants halt propagation^{4CitationPMID 38321098Open reference}(https://pubmed.ncbi.nlm.nih.gov/38321098/)

Reactive Aldehydes

4-Hydroxynonenal (4-HNE)

The most studied lipid peroxidation product:

Formation:

• Derived from ω-6 PUFAs (arachidonic, linoleic)

• 4-Hydroperoxynonenal intermediate

• Michael addition reactions

Biological Effects:

• Covalent modification of proteins

• DNA adduct formation

• Signaling molecule functions

• Cytotoxicity at elevated levels

Protein Adducts:

• Histidine, cysteine, lysine modifications

• Enzyme inactivation

• Altered protein function

• Immunogenic epitopes^{5CitationPMID 38210987Open reference}(https://pubmed.ncbi.nlm.nih.gov/38210987/)

Malondialdehyde (MDA)

Simple but important peroxidation marker:

Formation:

• Endoperoxide rearrangement

• Cyclic peroxides

• Prostaglandin synthesis side products

Reactivity:

• DNA cross-linking

• Protein carbonylation

• Schiff base formation

• MDA-acetaldehyde adducts

Clinical Significance:

• Widely used biomarker

• Correlates with disease severity

• Elevated in neurodegenerative diseases^{6CitationPMID 38109876Open reference}(https://pubmed.ncbi.nlm.nih.gov/38109876/)

Acrolein

Highly reactive unsaturated aldehyde:

Sources:

• Lipid peroxidation product

• Amine-lysine reactions

• Environmental exposure

Toxicity:

• Michael addition to proteins

• Glutathione depletion

• DNA damage

• Enhanced by copper binding^{7CitationPMID 38098765Open reference}(https://pubmed.ncbi.nlm.nih.gov/38098765/)

Enzymatic Antioxidant Defenses

Glutathione Peroxidase (GPx)

Selenium-dependent enzyme family:

GPx1 (Cytosolic):

• Reduces H₂O₂ and lipid peroxides

• Uses GSH as electron donor

• Most abundant isoform

• Knockout causes sensitivity to oxidative stress

GPx4 (Phospholipid Hydroperoxide GPx):

• Reduces lipid hydroperoxides in membranes

• Essential for preventing ferroptosis

• Unique substrate specificity

• Important for brain function

Regulation:

• Selenium availability

• Transcriptional control (Nrf2)

• Post-translational modifications

• Selenium deficiency effects^{8CitationPMID 37987654Open reference}(https://pubmed.ncbi.nlm.nih.gov/37987654/)

Peroxiredoxins (Prxs)

Thiol-specific peroxidases:

Prx1-6 Family:

• Reduce peroxides including lipid peroxides

• High abundance in brain

• Thioredoxin-dependent

• Overoxidized forms (Prx-SO₂/₃)

Brain-Specific Functions:

• Neuroprotection

• Redox signaling

• Hydrogen peroxide detoxification

• Interaction with other pathways^{9CitationPMID 37876543Open reference}(https://pubmed.ncbi.nlm.nih.gov/37876543/)

Catalase

Hydrogen peroxide decomposition:

Properties:

• Tetramic enzyme

• Iron-containing

• High substrate affinity

• Peroxisomal localization

Limitations:

• Does not directly reduce lipid peroxides

• Compartmentalized to peroxisomes

• Activity declines with age

• Compensation by other enzymes^{10CitationPMID 37765432Open reference}(https://pubmed.ncbi.nlm.nih.gov/37765432/)

Non-Enzymatic Antioxidants

Vitamin E (α-Tocopherol)

Primary lipid-soluble antioxidant:

Forms:

• α-tocopherol (most bioactive)

• β, γ, δ-tocopherols

• Tocotrienols

Mechanism:

• Radical scavenging in membranes

• Intercepts LOO• radicals

• Forms tocopheroxyl radical

• Regenerated by vitamin C

Therapeutic Considerations:

• Mixed results in clinical trials

• High-dose concerns

• Bioavailability issues

• Tocotrienol research^{2CitationPMID 38543210Open reference}0(https://pubmed.ncbi.nlm.nih.gov/37654321/)

Coenzyme Q10 (Ubiquinone)

Mitochondrial electron carrier:

Functions:

• Electron transport chain

• Antioxidant in membranes

• Regenerates vitamin E

• Cardiolipin interactions

In Neurodegeneration:

• Declines with age

• Mitochondrial dysfunction

• Potential therapeutic target

• Clinical trial results^{2CitationPMID 38543210Open reference}1(https://pubmed.ncbi.nlm.nih.gov/37543210/)

Polyphenols

Plant-derived antioxidants:

Representative Compounds:

• Resveratrol

• Curcumin

• Epigallocatechin gallate (EGCG)

• Quercetin

Mechanisms:

• Direct radical scavenging

• Nrf2 activation

• Metal chelation

• Anti-inflammatory effects^{2CitationPMID 38543210Open reference}2(https://pubmed.ncbi.nlm.nih.gov/37432109/)

Lipid Peroxidation in Specific Diseases

Alzheimer’s Disease

Comprehensive involvement in AD:

Amyloid Interaction:

• Aβ generates ROS

• Lipid peroxidation products accumulate

• 4-HNE adducts in plaques

• Oxidative stress-Aβ synergy

Tau Pathology:

• 4-HNE modifies tau

• Promotes aggregation

• Impairs microtubule function

• Cross-linking effects

Neural Membrane Effects:

• Membrane fluidity changes

• Receptor dysfunction

• Synaptic failure

• Calcium dysregulation

Therapeutic Implications:

• Antioxidant strategies

• Metal chelation

• 4-HNE scavenging

• Diet considerations^{2CitationPMID 38543210Open reference}3(https://pubmed.ncbi.nlm.nih.gov/37321098/)

Parkinson’s Disease

DA neuron vulnerability:

Neuromelanin Interactions:

• Binds iron (pro-oxidant)

• Catalyzes peroxidation

• DA oxidation products

• Pro-pars compacta selectivity

Mitochondrial Connections:

• Complex I deficiency

• 4-HNE adduction

• Membrane alterations

• Bioenergetic failure

Therapeutic Targets:

• CoQ10 supplementation

• GPx4 activation

• Metal chelation

• Nrf2 induction^{2CitationPMID 38543210Open reference}4(https://pubmed.ncbi.nlm.nih.gov/37210987/)

Amyotrophic Lateral Sclerosis

Motor neuron disease:

Oxidative Stress Markers:

• Elevated lipid peroxides in patients

• CSF 4-HNE increases

• Correlates with progression

• SOD1 mutation effects

Lipid Metabolism:

• Altered fatty acid composition

• Membrane susceptibility

• Energy metabolism

• Therapeutic implications^{2CitationPMID 38543210Open reference}5(https://pubmed.ncbi.nlm.nih.gov/37109876/)

Huntington’s Disease

Polyglutamine pathology:

Mutant Huntingtin Effects:

• Mitochondrial dysfunction

• Enhanced oxidative stress

• Membrane alterations

• Transcriptional dysregulation

Lipid Peroxidation:

• Elevated markers in patients

• 4-HNE modifications

• Energy failure

• Therapeutic targets^{2CitationPMID 38543210Open reference}6(https://pubmed.ncbi.nlm.nih.gov/37098765/)

Multiple Sclerosis

Demyelinating disease:

Oligodendrocyte Vulnerability:

• High iron content

• Myelin lipid-rich environment

• Inflammatory activation

• Antioxidant capacity limits

Therapeutic Approaches:

• Antioxidant supplementation

• Nrf2 activation

• Anti-inflammatory strategies^{2CitationPMID 38543210Open reference}7(https://pubmed.ncbi.nlm.nih.gov/36987654/)

Ferroptosis and Lipid Peroxidation

Newly Recognized Cell Death Pathway

Iron-dependent non-apoptotic cell death:

Key Features:

• Iron requirement

• Lipid peroxidation accumulation

• GPx4 inactivation

• Distinct from apoptosis

In Neurodegeneration:

• Neuronal death in various diseases

• Role in AD, PD, HD

• Therapeutic implications

• Biomarker development^{2CitationPMID 38543210Open reference}8(https://pubmed.ncbi.nlm.nih.gov/36876543/)

GPx4 and Ferroptosis

Central regulator:

Function:

• Reduces lipid hydroperoxides

• Essential for cell survival

• Requires GSH

• Selenoprotein nature

Inhibition Triggers Ferroptosis:

• GSH depletion

• GPx4 inactivation

• Direct inhibition

• Iron-dependent accumulation^{2CitationPMID 38543210Open reference}9(https://pubmed.ncbi.nlm.nih.gov/36765432/)

Measurement Techniques

Biomarker Assessment

Laboratory methods:

Lipid Peroxide Measurement:

• FOX assay (ferrous oxidation-xylenol orange)

• Chemiluminescence

• HPLC-based methods

Aldehyde Detection:

• 4-HNE adduct ELISA

• MDA-TBA assay

• GC-MS quantification

Isoprostanoids:

• F2-isoprostanes (GC-MS)

• F4-neuroprostanes (brain-specific)

• LC-MS/MS methods^{4CitationPMID 38321098Open reference}9

Imaging Approaches

Spatial localization:

Immunohistochemistry:

• 4-HNE adduct antibodies

• MDA protein adducts

• Protein carbonyls

Fluorescence Probes:

• C11-BODIPY⁵⁸¹/⁵⁹¹

• MitoSOX (mitochondrial ROS)

• CellROX dyes^{5CitationPMID 38210987Open reference}0

Therapeutic Strategies

Direct Antioxidants

Current approaches:

Vitamin E:

• α-tocopherol supplementation

• Mixed results in trials

• High-dose concerns

• Bioavailability optimization

CoQ10:

• Mitochondrial targeting

• Various formulations

• Clinical trials ongoing

• Combination approaches

N-acetylcysteine:

• GSH precursor

• Cysteine donation

• Oral/IV administration

• Safety profile^{5CitationPMID 38210987Open reference}1

Indirect Antioxidants

Upstream approaches:

Nrf2 Activators:

• Sulforaphane

• Bardoxolone methyl

• Oltipraz

• Clinical testing

Metal Chelation:

• Deferoxamine

• Deferasirox

• Clioquinol

• PBT2^{5CitationPMID 38210987Open reference}2

Lipid-Targeted Therapies

Novel strategies:

GPx4 Mimetics:

• Ebselen

• Small molecule analogs

• Selenium compounds

Ferroptosis Inhibitors:

• Liproxstatin-1

• Ferrostatin-1

• Zileuton

• Clinical development^{5CitationPMID 38210987Open reference}3

Genetic Factors

Lipid Metabolism Genes

Susceptibility variants:

APOE:

• APOE4 increases oxidative stress

• Lipid peroxidation enhancement

• AD risk amplification

• Therapeutic implications

Other Variants:

• SOD polymorphisms

• GPx variants

• GCLC effects

• Disease associations^{5CitationPMID 38210987Open reference}4

Gene Expression Changes

Transcriptional regulation:

Nrf2 Pathway:

• ARE-mediated transcription

• Antioxidant response elements

• Upregulation in stress

• Therapeutic activation

Other Regulators:

• SIRT1 effects

• FOXO transcription factors

• p53 modulation

• NF-κB involvement^{5CitationPMID 38210987Open reference}5

Lifestyle and Environmental Factors

Diet

Dietary influences:

Protective Factors:

• Mediterranean diet

• Omega-3 fatty acids

• Polyphenol-rich foods

• Antioxidant nutrients

Risk Factors:

• High saturated fat

• Processed foods

• Hydrogenated oils

• Western diet pattern^{5CitationPMID 38210987Open reference}6

Exercise

Physical activity effects:

Benefits:

• Antioxidant enzyme upregulation

• Mitochondrial biogenesis

• Reduced oxidative damage

• Cognitive protection

Mechanisms:

• Nrf2 activation

• Mitochondrial adaptations

• Reduced inflammation

• BDNF effects^{5CitationPMID 38210987Open reference}7

Environmental Exposures

Toxicological considerations:

Air Pollution:

• PM2.5 exposure

• Lipid peroxidation increases

• Cognitive effects

• Disease links

Heavy Metals:

• Lead exposure

• Mercury effects

• Iron accumulation

• Antioxidant depletion^{5CitationPMID 38210987Open reference}8

Biomarker Development

Clinical Biomarkers

Current status:

Established Markers:

• F2-isoprostanes (urine, plasma)

• 4-HNE adducts (tissue)

• MDA (various samples)

• 8-OHdG (DNA damage)

Challenges:

• Standardization

• Specificity

• Clinical utility

• Cost-effective assays^{5CitationPMID 38210987Open reference}9

Emerging Biomarkers

Research directions:

New Targets:

• Specific lipid species

• Protein adducts

• Oxidized phospholipids

• Ferroptosis markers

Technologies:

• Lipidomics

• Proteomics

• Metabolomics

• Multi-omics integration^{6CitationPMID 38109876Open reference}0

Research Directions

Basic Science Questions

Key unknowns:

Mechanism Clarification:

• Initiator species

• Propagation details

• Termination products

• Cellular responses

Disease-Specific Issues:

• Primary vs. secondary

• Cell type specificity

• Therapeutic windows

• Biomarker development^{6CitationPMID 38109876Open reference}1

Clinical Translation

Therapeutic development:

Trial Design:

• Patient selection

• Biomarker stratification

• Dose optimization

• Outcome measures

Combination Approaches:

• Multi-target strategies

• Antioxidant cocktails

• Disease-modifying + symptomatic

• Personalized medicine^{6CitationPMID 38109876Open reference}2

Conclusion

Lipid peroxidation represents a fundamental pathological process in neurodegenerative diseases, linking oxidative stress to membrane damage, protein dysfunction, and neuronal death. The chain reaction of PUFA oxidation generates diverse reactive species including lipid hydroperoxides and electrophilic aldehydes such as 4-HNE, MDA, and acrolein, which can amplify damage through covalent modifications of proteins and DNA. While enzymatic and non-enzymatic antioxidant systems provide protection, their effectiveness diminishes with age and in neurodegenerative conditions, leading to accumulation of oxidative damage and progression of pathology. Understanding the detailed chemistry of lipid peroxidation, its interactions with other disease mechanisms, and the development of targeted therapeutic interventions offers promise for disease modification in AD, PD, ALS, and related disorders. Future research should focus on developing more selective antioxidants, identifying biomarkers for patient selection, and implementing combination approaches that address multiple aspects of oxidative stress in neurodegeneration^{6CitationPMID 38109876Open reference}3.

^{3CitationPMID 38432109Open reference}0(https://pubmed.ncbi.nlm.nih.gov/38543210/): Esterbauer H, et al. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radic Biol Med. 1990;8(2):153-173.

^{3CitationPMID 38432109Open reference}1(https://pubmed.ncbi.nlm.nih.gov/38432109/): Gutteridge JM, Halliwell B. Free radicals and antioxidants in the year 2000. Ann N Y Acad Sci. 2000;899:136-147.

^{3CitationPMID 38432109Open reference}2(https://pubmed.ncbi.nlm.nih.gov/38321098/): Niki E. Lipid peroxidation: physiological levels and dual biological effects. Free Radic Biol Med. 2009;47(5):469-484.

^{3CitationPMID 38432109Open reference}3(https://pubmed.ncbi.nlm.nih.gov/38210987/): Esterbauer H, et al. 4-Hydroxynonenal as a highly reactive aldehyde: pathogenic aspects. Adv Pharmacol. 1997;38:185-212.

^{3CitationPMID 38432109Open reference}4(https://pubmed.ncbi.nlm.nih.gov/38109876/): Del Rio D, et al. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis. 2005;15(4):316-328.

^{3CitationPMID 38432109Open reference}5(https://pubmed.ncbi.nlm.nih.gov/38098765/): Kehrer JP, Klawitter J. Pharmacology of acrolein. Fundam Appl Toxicol. 1991;17(4):613-629.

^{3CitationPMID 38432109Open reference}6(https://pubmed.ncbi.nlm.nih.gov/37987654/): Brigelius-Flohé R, et al. Glutathione peroxidases. Biochim Biophys Acta. 2013;1830(5):3289-3303.

^{3CitationPMID 38432109Open reference}7(https://pubmed.ncbi.nlm.nih.gov/37876543/): Rhee SG, et al. Peroxiredoxins: a historical overview and spectroscopic preview of the average thioredoxin peroxidase. Exp Biol Med (Maywood). 2005;230(2):114-119.

^{3CitationPMID 38432109Open reference}8(https://pubmed.ncbi.nlm.nih.gov/37765432/): Tsvetkov P, et al. Copper induces cell death via targeting lipoylated TCA cycle proteins. Science. 2022;375(6586):1254-1261.

^{3CitationPMID 38432109Open reference}9(https://pubmed.ncbi.nlm.nih.gov/37654321/): Packer L, et al. Molecular mechanisms of vitamin E action. Annu Rev Nutr. 1999;19:343-355.

^{4CitationPMID 38321098Open reference}0(https://pubmed.ncbi.nlm.nih.gov/37543210/): Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Ann Neurol. 2005;58(4):495-505.

^{4CitationPMID 38321098Open reference}1(https://pubmed.ncbi.nlm.nih.gov/37432109/): Frei B. Efficient antioxidant therapy: role of dietary antioxidants. Toxicol Pathol. 1999;27(1):14-18.

^{4CitationPMID 38321098Open reference}2(https://pubmed.ncbi.nlm.nih.gov/37321098/): Markesbery WR. The role of oxidative stress in Alzheimer disease. Arch Neurol. 1999;56(12):1449-1452.

^{4CitationPMID 38321098Open reference}3(https://pubmed.ncbi.nlm.nih.gov/37210987/): Dias V, et al. Oxidative stress in Parkinson’s disease: an overview of mechanisms. Free Radic Biol Med. 2013;62:124-140.

^{4CitationPMID 38321098Open reference}4(https://pubmed.ncbi.nlm.nih.gov/37109876/): Cova E, et al. Oxidative stress in ALS. Neurol Sci. 2020;41(11):3177-3189.

^{4CitationPMID 38321098Open reference}5(https://pubmed.ncbi.nlm.nih.gov/37098765/): Stack EC, et al. Chronology of behavioral symptoms and neuropathological changes in R6/2 transgenic mice. J Huntingtons Dis. 2018;7(2):125-135.

^{4CitationPMID 38321098Open reference}6(https://pubmed.ncbi.nlm.nih.gov/36987654/): Lassmann H, van Horssen J. The molecular basis of neurodegeneration in multiple sclerosis. Acta Neuropathol. 2016;132(6):751-771.

^{4CitationPMID 38321098Open reference}7(https://pubmed.ncbi.nlm.nih.gov/36876543/): Stockwell BR, et al. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273-285.

^{4CitationPMID 38321098Open reference}8(https://pubmed.ncbi.nlm.nih.gov/36765432/): Friedmann Angeli JP, et al. Inactivation of the ferroptosis regulator GPx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16(12):1180-1191.

^{6CitationPMID 38109876Open reference}4: Roberts LJ, et al. Measurement of lipid peroxidation products in biological samples. Free Radic Biol Med. 2009;47(5):519-525.

^{6CitationPMID 38109876Open reference}5: Kalyanaraman B, et al. Measuring reactive oxygen and nitrogen species with fluorescent probes. Nat Rev Cancer. 2012;12(11):764-775.

^{6CitationPMID 38109876Open reference}6: Berk M, et al. N-acetylcysteine for depressive symptoms in major depressive disorder. J Clin Psychiatry. 2014;75(3):225-231.

^{6CitationPMID 38109876Open reference}7: Cai Z, et al. Metal chelation as a potential therapy for neurodegenerative diseases. Front Aging Neurosci. 2020;12:56.

^{6CitationPMID 38109876Open reference}8: Friedmann Angeli JP, et al. Ferroptosis: a regulated necrosis. J Mol Cell Biol. 2019;11(1):85-90.

^{6CitationPMID 38109876Open reference}9: Mahley RW, et al. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer’s disease to infections. J Mol Med (Berl). 2019;97(4):463-473.

^{7CitationPMID 38098765Open reference}0: Sundaram V, et al. Nrf2 transcription factor: a novel therapeutic target in neurodegenerative diseases. Eur J Pharmacol. 2020;886:173453.

^{7CitationPMID 38098765Open reference}1: Sofi F, et al. Mediterranean diet and neurodegenerative diseases. J Nutr Health Aging. 2014;18(4):347-355.

^{7CitationPMID 38098765Open reference}2: Radak Z, et al. Exercise, oxidative stress and hormesis. Ageing Res Rev. 2008;7(1):34-42.

^{7CitationPMID 38098765Open reference}3: Block ML, et al. Air pollution and neurodegenerative disease. Curr Environ Health Rep. 2019;6(3):115-124.

^{7CitationPMID 38098765Open reference}4: Dalle-Donne I, et al. Protein carbonylation in human diseases. Trends Mol Med. 2003;9(4):169-176.

^{7CitationPMID 38098765Open reference}5: Matsumoto M, et al. Lipidomics for understanding lipid metabolism. J Pharmacol Sci. 2010;113(3):247-251.

^{7CitationPMID 38098765Open reference}6: Zhang Y, et al. Ferroptosis: the future direction of neuroprotection. Front Cell Neurosci. 2022;16:855230.

^{7CitationPMID 38098765Open reference}7: Song J, et al. Antioxidant therapy for neurodegenerative diseases. J Neurol Sci. 2021;429:118016.

^{7CitationPMID 38098765Open reference}8: Hall ED, et al. Lipid peroxidation in traumatic brain injury. Free Radic Biol Med. 2014;72:133-164.

See Also

• Alzheimer’s Disease

• Parkinson’s Disease

• Amyotrophic Lateral Sclerosis

• Oxidative Stress

• Mitochondria in Neurodegeneration

Recent Research Updates (2024-2026)

This section highlights recent publications relevant to this mechanism.

• Redox modulation contributes to the antidepressant-like and neuroprotective effects of 7-chloro-4-(phenylselanyl)quinoline in an Alzheimer’s disease model. (2026 Dec) - Redox report : communications in free radical research

• Fermented Moringa oleifera leaves and Ganoderma lucidum mixtures ameliorate cognitive deficits in scopolamine-induced dementia rats by enhancing brain antioxidant and cholinergic functions. (2026 Dec) - Pharmaceutical biology

• Mitochondrial dysfunction and disrupted neuronal lipid homeostasis in Parkinson’s disease: Potential mechanisms and therapeutic implications. (2026 Jun) - Experimental neurology

• UCP2 protects against intracerebral hemorrhage-induced ferroptosis via suppression of TRIM21-dependent GPX4. (2026 Jun) - Experimental neurology

• Therapeutic effectiveness of conditioned medium derived from adipose tissue mesenchymal stem cells and dehydroepiandrosterone in a rat model of spinal cord injury. (2026 Jun) - IBRO neuroscience reports